U.S. Metals and Mining Stock News

Zscaler has been named the 2026 Google Cloud Partner of the Year for Security in the Application category. The recognition highlights Zscaler’s role in AI security within the Google Cloud ecosystem. The award adds fresh industry validation to Zscaler’s position in the cybersecurity market. Zscaler (NasdaqGS:ZS), trading at $139.61, is getting fresh attention after being recognized by Google Cloud as its 2026 Partner of the Year for Security in the Application category. The stock has seen a...

Investors may be wondering whether GE Vernova's share price still offers value after a strong run, or if most of the easy gains are already on the table. The stock last closed at US$991.30, with returns of 0.4% over 7 days, 16.5% over 30 days, 45.9% year to date, and 204.7% over the past year, which can change how investors think about both opportunity and risk. Recent coverage has focused on GE Vernova as a newly listed, pure play power and energy transition business and how the stock has...

CSB Bancorp (CSBB) has put up a clean set of numbers for Q1 2026, with Q4 2025 revenue at US$9.5 million, basic EPS at US$0.71, and net income of US$1.9 million anchoring the latest run of results against a trailing year where earnings grew 33.5% and net profit margin sat at 30.2%. Over recent quarters, revenue has moved from US$9.1 million in Q4 2024 to US$11.0 million in Q1 2025, US$11.5 million in Q2 2025, US$12.3 million in Q3 2025, then US$9.5 million in Q4 2025, with EPS shifting from...

Alaska Air Group (ALK) has opened 2026 with Q1 revenue of US$3.3b and a basic EPS loss of US$1.69, compared with a trailing twelve month basic EPS of US$0.63 on revenue of US$14.4b that produced net income of US$73m. Over recent quarters, revenue has moved from US$3.1b in Q1 2025 to US$3.6b in Q4 2025 before landing at US$3.3b in the latest period. Quarterly EPS has swung from a loss of US$1.35 in Q1 2025 to a profit of US$1.45 in Q2 2025 and back to a loss in Q1 2026, leaving investors...

Northern Trust (NTRS) has opened Q1 2026 earnings season with a recent run of quarterly results that show total revenue moving from US$1,960.5 million in Q3 2024 to US$2,131.1 million in Q4 2025, alongside quarterly EPS stepping up from US$2.23 to US$2.44 over the same period. Over the last reported trailing twelve months to Q1 2026, revenue has ranged between US$7.9 billion and US$8.6 billion, with EPS running between about US$8.5 and US$10.8. This provides a basis for investors to weigh...

3M (MMM) has just opened its Q1 2026 reporting season conversation with a recent run of results that saw quarterly revenue range from US$5.95 billion to US$6.52 billion through 2025, alongside basic EPS moving between US$1.08 and US$2.05 as net income fluctuated from US$577 million to US$1.12 billion. Over the same stretch, revenue has moved from US$6.01 billion in Q4 2024 to US$6.13 billion in Q4 2025, while basic EPS shifted from US$1.34 to US$1.08. This sets a backdrop where investors are...

BOK Financial (BOKF) opened 2026 with Q1 revenue of US$553.8 million and basic EPS of US$2.59, while trailing twelve month revenue sat at US$2.23 billion and EPS at US$9.88. This provides a clear snapshot of the bank's recent earnings power. Over the past year, revenue has moved from US$2.03 billion to US$2.23 billion and trailing twelve month EPS has gone from US$8.14 to US$9.88, giving investors a cleaner read on how the income statement is scaling. With net income on a trailing basis at...

RTX (RTX) opened the new year with Q1 2026 results coming on the heels of Q4 2025 revenue of US$24.2b and basic EPS of US$1.21, supported by Q4 net income of US$1.6b. Over the last six reported quarters, revenue moved from US$21.6b in Q4 2024 to US$24.2b in Q4 2025, while quarterly basic EPS ranged from US$1.10 to US$1.43. This sets up trailing twelve month EPS of US$5.02 and net income of US$6.7b as the reference point for today’s update, so the focus now is on how Q1 margins held up against...

Halliburton (HAL) has just opened its books on the latest period, with trailing 12 month revenue most recently sitting at about US$22.2b and basic EPS shifting from US$2.84 a year ago to US$1.50 on the most recent trailing view, setting a very different earnings backdrop for investors to interpret. Over the last reported quarters, quarterly revenue has moved between US$5,417m and US$5,697m while basic EPS has ranged from US$0.02 to around US$0.70, giving a wide spread of earnings outcomes...

Mercantile Bank (MBWM) just posted another quarter of steady profitability, with Q4 2025 revenue at US$61.8 million and net income of US$22.8 million, which translates into basic EPS of US$1.40 ahead of its Q1 2026 reporting period. Over recent quarters the bank has seen revenue move from US$56.3 million in Q4 2024 to US$61.8 million in Q4 2025, while basic EPS increased from US$1.22 to US$1.40, giving investors a clear picture of consistent earnings power heading into the new year. With...

Fermi Inc. recently reshaped its leadership and governance, with co-founder Toby Neugebauer stepping down as CEO, Miles Everson resigning as CFO to join the board, the creation of an interim Office of the CEO led by Co-Presidents Jacobo Ortiz Blanes and Anna Bofa, and the appointment of Jeffrey S. Stein as a new director, while also committing to new headquarters in Dallas and expanded offices at Project Matador in Amarillo. Together, these moves mark a shift from founder-led management to a...

On April 15, 2026, Organon & Co. reported that VTAMA (tapinarof) cream received a strong, evidence-based recommendation in the American Academy of Dermatology’s first pediatric atopic dermatitis guidelines, which recognize it as the only steroid-free topical supported by high-certainty evidence for children aged 2 and older across all disease severities. This endorsement strengthens VTAMA’s clinical profile in a large pediatric eczema population, potentially reinforcing Organon’s...

Western Midstream Partners, LP previously announced that its board declared a first‑quarter 2026 cash distribution of US$0.93 per unit, a 2.2% increase over the prior quarter, payable on May 15, 2026 to unitholders of record on May 1, 2026. This distribution increase, alongside management’s emphasis on sustaining a high yield backed by fee-based midstream cash flows, underscores the partnership’s focus on income-oriented returns. We’ll now examine how the higher US$0.93 quarterly...

Why the AACR data on rinzimetostat is on investors’ radar ORIC Pharmaceuticals (ORIC) shares are in focus after the company highlighted new preclinical data for rinzimetostat at the 2026 AACR Annual Meeting, centered on prostate cancer models that include treatment resistant disease. See our latest analysis for ORIC Pharmaceuticals. ORIC’s latest AACR posters on rinzimetostat arrive after a strong year to date, with a 33.29% year to date share price return and a 123.61% 1 year total...

Septerna, Inc. recently began dosing healthy volunteers in a randomized, placebo-controlled Phase 1 trial of SEP-479, an oral PTH1R agonist for hypoparathyroidism, using single-ascending and multiple-ascending dose designs to assess safety, tolerability, pharmacokinetics and pharmacodynamics. This first-in-human study, which could enroll up to 150 participants and tracks biomarkers such as endogenous PTH and serum calcium, marks a key progression of Septerna’s GPCR-targeted pipeline into...

Over the last 7 days, the United States market has risen by 3.6%, and over the past year, it has seen a remarkable increase of 39%, with earnings forecasted to grow by 16% annually. In such a thriving environment, identifying stocks that are potentially undervalued can offer opportunities for investors looking to capitalize on discrepancies between current prices and estimated worth.

The United States market has shown robust performance, climbing 3.6% in the last week and 39% over the past year, with earnings projected to grow by 16% annually. In this thriving environment, stocks with high insider ownership can be particularly appealing as they often signal confidence from those closest to the company's operations and strategic direction.

Over the last 7 days, the United States market has risen 3.6%, and over the past year, it has climbed 39%, with earnings expected to grow by 16% annually. Penny stocks may be a throwback term, but they still offer intriguing opportunities for investors seeking growth at lower price points. By focusing on those with strong balance sheets and solid fundamentals, these stocks can present an underappreciated chance for stability and potential upside in today's market conditions.

The United States market has experienced a notable upswing, climbing 3.6% over the last week and an impressive 39% over the past year, with earnings projected to grow by 16% annually. In such a dynamic environment, identifying stocks that are not only poised for growth but also remain under the radar can offer unique opportunities for investors seeking to capitalize on market momentum while discovering potential value.

Gogo Inc. ( NASDAQ:GOGO ), is not the largest company out there, but it received a lot of attention from a substantial...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

At its April 13, 2026 annual meeting, Otter Tail Corporation approved amended and restated bylaws adding an exclusive forum provision and announced key leadership changes, including appointing Tim Rogelstad as President and Tyler Nelson as Chief Financial Officer. By concentrating litigation in a designated court and elevating long-tenured utility leaders into top corporate roles, Otter Tail is tightening legal control while reinforcing continuity in its electric and manufacturing...

Investors may be considering whether Universal Health Services offers good value at its current share price, or whether the recent share price move has already reflected much of the opportunity. The stock last closed at US$179.72, with a 1.9% decline over 7 days, a 3.3% decline over 30 days, an 18.3% decline year to date, and a 14.9% gain over the past year. Recent coverage has focused on Universal Health Services as a major player in US healthcare services, with ongoing attention on how...

Ocular Therapeutix (NasdaqGM:OCUL) released new 52-week post hoc Phase 3 data for AXPAXLI in wet age-related macular degeneration. The SOL-1 trial data indicated better durability, strong sustained disease control, and safety outcomes compared to aflibercept. The company presented the findings at a major ophthalmology conference and plans to seek FDA approval with a single pivotal Phase 3 trial. Ocular Therapeutix focuses on therapies for eye diseases, with AXPAXLI (OTX TKI) aimed at...